Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition

Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Luka, Miyatsuka, Takeshi, Himuro, Miwa, Nishio, Rie, Goto, Hiromasa, Uchida, Toyoyoshi, Nishida, Yuya, Kanazawa, Akio, Watada, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007247/
https://www.ncbi.nlm.nih.gov/pubmed/29942923
http://dx.doi.org/10.1210/js.2017-00475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007247/
https://www.ncbi.nlm.nih.gov/pubmed/29942923
http://dx.doi.org/10.1210/js.2017-00475

Ejemplares similares